The long-term goal of this proposal is to understand the regulation of G protein-coupled receptor (GPCR) signaling by endocytic trafficking. GPCRs comprise the largest family of signaling receptors expressed in the mammalian genome, mediate cellular responses to diverse stimuli and control vast physiological responses. Dysregulated GPCR signaling has been implicated in neurological disorders, cardiovascular diseases and cancer progression, making this receptor class the target of nearly half the drugs used clinically. In addition to desensitization, GPCR trafficking is crucial for the temporal and spatial control of receptor signaling. This is best exemplified by protease-activated receptor-1 (PAR1), a GPCR for the coagulant protease thrombin. PAR1 has important functions in vascular physiology, development and tumor progression and is an important drug target. Similar to most GPCRs, signaling by activated PAR1 is rapidly desensitized. We also found that activated PAR1 internalization and lysosomal sorting is critical for the fidelity of thrombin signaling and appropriate cellular responses. We further discovered that activated PAR1 trafficking is dysregulated in metastatic breast carcinoma, consequently the receptor recycles to the cell surface, signals persistently and promotes tumor progression. The mechanisms responsible for dysregulation of PAR1 trafficking are not known and important to understand. Many GPCRs are modified with ubiquitin and sorted to lysosomes through interactions with ubiquitin-binding components of the ESCRT machinery. However, not all GPCRs require direct ubiquitination for lysosomal sorting including PAR1. We recently discovered a novel lysosomal sorting pathway that bypasses the requirement for receptor ubiquitination and ubiquitin-binding ESCRTs that is mediated by ALIX. ALIX, a CHMP4/ESCRT-III interacting protein, bound to an YPX3L motif of PAR1 via its V domain and mediated PAR1 lysosomal sorting. We also identified a subset of class A GPCRs containing YPXnL motifs, suggesting that this pathway may be applicable to other GPCRs. Our preliminary studies further indicate that the ALIX-interacting protein arrestin-domain containing protein -3 (ARRDC3) regulates PAR1 degradation. ARRDC3 appears to function as a tumor suppressor and its expression is lost in invasive breast carcinoma that exhibit dysregulated PAR1 trafficking. Moreover, ectopic expression of ARRDC3 promoted lysosomal sorting of PAR1 in invasive breast carcinoma. The proposed studies will advance our understanding of how ARRDC3 and ALIX function to regulate GPCR intracellular trafficking and signaling in normal and cancer cells.
The specific aims of the proposal are to: 1) determine whether ARRDC3 regulates GPCR sorting to late endosomes/multivesicular bodies, 2) delineate the regulatory mechanisms of ALIX function in lysosomal sorting of GPCRs, and 3) examine the role of ARRDC3 in dysregulated GPCR trafficking in cancer.

Public Health Relevance

The proposed research is relevant to public health because it seeks to understand the regulation of G protein-coupled receptor (GPCR) signaling. GPCRs are the largest family of signaling receptors in mammalian cells, mediate vast physiological responses, and are the largest class of drug targets for therapeutics used clinically. However, the regulation of GPCR signaling remains poorly understood and discovering new aspects of GPCR signal regulation is critical for future drug development that could ultimately lead to the identification of new drug targets relevant to a wide range of human diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
2R01GM090689-05
Application #
8652182
Study Section
Molecular Neuropharmacology and Signaling Study Section (MNPS)
Program Officer
Dunsmore, Sarah
Project Start
2010-01-01
Project End
2017-12-31
Budget Start
2014-02-01
Budget End
2014-12-31
Support Year
5
Fiscal Year
2014
Total Cost
$329,375
Indirect Cost
$116,875
Name
University of California San Diego
Department
Pharmacology
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Kawamura, Tetsuya; Stephens, Bryan; Qin, Ling et al. (2014) A general method for site specific fluorescent labeling of recombinant chemokines. PLoS One 9:e81454
Grimsey, Neil; Lin, Huilan; Trejo, JoAnn (2014) Endosomal signaling by protease-activated receptors. Methods Enzymol 535:389-401
Dores, Michael R; Trejo, JoAnn (2014) Atypical regulation of G protein-coupled receptor intracellular trafficking by ubiquitination. Curr Opin Cell Biol 27:44-50
Chen, Buxin; Siderovski, David P; Neubig, Richard R et al. (2014) Regulation of protease-activated receptor 1 signaling by the adaptor protein complex 2 and R4 subfamily of regulator of G protein signaling proteins. J Biol Chem 289:1580-91
Lin, Huilan; Liu, Allen P; Smith, Thomas H et al. (2013) Cofactoring and dimerization of proteinase-activated receptors. Pharmacol Rev 65:1198-213
Gilliland, C Taylor; Salanga, Catherina L; Kawamura, Tetsuya et al. (2013) The chemokine receptor CCR1 is constitutively active, which leads to G protein-independent, *-arrestin-mediated internalization. J Biol Chem 288:32194-210
Lin, Huilan; Trejo, JoAnn (2013) Transactivation of the PAR1-PAR2 heterodimer by thrombin elicits ?-arrestin-mediated endosomal signaling. J Biol Chem 288:11203-15
Canto, Isabel; Trejo, JoAnn (2013) Palmitoylation of protease-activated receptor-1 regulates adaptor protein complex-2 and -3 interaction with tyrosine-based motifs and endocytic sorting. J Biol Chem 288:15900-12
Dores, Michael R; Chen, Buxin; Lin, Huilan et al. (2012) ALIX binds a YPX(3)L motif of the GPCR PAR1 and mediates ubiquitin-independent ESCRT-III/MVB sorting. J Cell Biol 197:407-19
Grimsey, Neil; Soto, Antonio G; Trejo, JoAnn (2011) Regulation of protease-activated receptor signaling by post-translational modifications. IUBMB Life 63:403-11

Showing the most recent 10 out of 11 publications